Sugi Predict

Sugi Predict / Targets / CCNO

CCNO

Cyclin-O · P22674 · CCNO on Sugi Atlas →

132 patent compounds predicted against CCNO, 99 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL6166973 SCHEMBL6166973 0.52 3/20
SCHEMBL6164565 SCHEMBL6164565 1.00 2/20
SCHEMBL6164644 SCHEMBL6164644 0.76 2/20
SCHEMBL6164739 SCHEMBL6164739 0.76 2/20
SCHEMBL6163398 SCHEMBL6163398 0.72 2/20
SCHEMBL6164744 SCHEMBL6164744 0.72 2/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL6164285) 0.71 2/20
SCHEMBL6165103 SCHEMBL6165103 0.71 2/20
SCHEMBL6165107 SCHEMBL6165107 0.71 2/20
SCHEMBL6165208 SCHEMBL6165208 0.70 2/20
SCHEMBL6163976 SCHEMBL6163976 0.67 2/20
SCHEMBL6165336 SCHEMBL6165336 0.49 2/20
SCHEMBL6165339 SCHEMBL6165339 0.49 2/20
SCHEMBL16179628 SCHEMBL16179628 1.00 1/20
SCHEMBL16189638 SCHEMBL16189638 1.00 1/20
SCHEMBL21067774 SCHEMBL21067774 1.00 1/20
SCHEMBL21618367 SCHEMBL21618367 1.00 1/20
SCHEMBL21622451 SCHEMBL21622451 1.00 1/20
SCHEMBL21622452 SCHEMBL21622452 1.00 1/20
SCHEMBL31028540 SCHEMBL31028540 1.00 1/20

Clinical trials — most relevant to CCNO by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI PHASE2COMPLETED
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO PHASE2COMPLETED
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors PHASE2WITHDRAWN
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors PHASE1/PHASE2COMPLETED
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Study of AVZO-021 in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) PHASE2COMPLETED
Abemaciclib + Pembrolizumab In Glioblastoma PHASE2WITHDRAWN
Palbociclib and Pembrolizumab In Central Nervous System Metastases PHASE2RECRUITING
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors PHASE1COMPLETED
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) PHASE1SUSPENDED
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors PHASE1RECRUITING
Tamoxifen in Patients With Oesophageal Cancer PHASE1UNKNOWN
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets PHASE1UNKNOWN
The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence nanUNKNOWN
Co'Moon for Supporting Breast Cancer Patients on Adjuvant Endocrine Therapy nanCOMPLETED
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy nanUNKNOWN
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer nanCOMPLETED
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CCNO binder may also engage these)

ProteinNameSimilarity
P0C242 — 0.989 P0C242 →
Q5F2F2 — 0.936 Q5F2F2 →
Q9Z2V9 — 0.935 Q9Z2V9 →
PML Protein PML 0.934 landscape →
Q6UXT9 — 0.933 Q6UXT9 →
CCNI Cyclin-I 0.933 landscape →
Q96NA8 — 0.930 Q96NA8 →
Q8N1F8 — 0.929 Q8N1F8 →
Q9ESG9 — 0.929 Q9ESG9 →
Q96JH8 — 0.927 Q96JH8 →
Q5SRT8 — 0.927 Q5SRT8 →
Q86WI3 — 0.926 Q86WI3 →
Q7Z4K8 — 0.925 Q7Z4K8 →
PPM1F Protein phosphatase 1F 0.925 landscape →
Q96DC7 — 0.923 Q96DC7 →
Q32PI0 — 0.923 Q32PI0 →
O18796 — 0.923 O18796 →
X6R8R1 — 0.923 X6R8R1 →
O95685 — 0.923 O95685 →
Q9Z335 — 0.923 Q9Z335 →
Q32NM1 — 0.922 Q32NM1 →
SBK1 Serine/threonine-protein kinase SBK1 0.922 landscape →
Q0GA42 — 0.921 Q0GA42 →
Q8BQX5 — 0.921 Q8BQX5 →
PKMYT1 Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase 0.921 landscape →
Q8N9H8 — 0.921 Q8N9H8 →
Q8N531 — 0.920 Q8N531 →
D3YZZ2 — 0.920 D3YZZ2 →
Q8WXI3 — 0.920 Q8WXI3 →
Q9PW70 — 0.919 Q9PW70 →